ArticleNews reportPHN-05492026-11-02 02:44 CT

Novo Nordisk stock sets obesity data focus ahead of ObesityWeek - ad-hoc-news.de

Source · Google News

TLDR

Novo Nordisk says it will present obesity research at ObesityWeek in Washington, D.C., November 14–17, 2026. Planned presentations include CagriSema trial results, real-world Wegovy research and semaglutide findings in children aged 6 to under 12; the article does not report study outcomes.

01—Key points

01The company plans primary REDEFINE 9 results and post-hoc REDEFINE 1 analyses; CagriSema remains unapproved, with safety and efficacy unestablished.
02Wegovy-related research will cover treatment preferences, telehealth use and food noise, alongside oral semaglutide patient-support outcomes.
03Full STEP Young results will address semaglutide in children aged 6 to under 12, an investigational age group.

Why it matters Editorial

The planned presentations may provide additional evidence on Novo Nordisk’s investigational obesity treatments and real-world treatment experience.

Read the original at Google News↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.